A PYMNTS Company

US: Celgene to pay Mylan $62M to resolve cancer drug antitrust case

By  |  July 31, 2019

Mylan announced Celgene will pay it US$62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Mylan disclosed the settlement in a filing with the US Securities and Exchange Commission on Monday, July 29, days after Celgene agreed to pay US$55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.